학술논문
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
Document Type
Article
Author
Source
In: Journal for ImmunoTherapy of Cancer . (Journal for ImmunoTherapy of Cancer, 13 February 2020, 8(1))
Subject
Language
English
ISSN
20511426